HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): John S. Ikonomidis John M. Kratz Arthur J. Crumbley, III Scott M. Bradley Robert M. Sade Fred A. Crawford, Jr Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikonomidis, J. S. Articles by Crawford, F. A. Search for Related Content PubMed PubMed Citation Articles by Ikonomidis, J. S. Articles by Crawford, F. A., Jr Related Collections Valve disease

J Thorac Cardiovasc Surg 2003;126:2022-2031
© 2003 The American Association for Thoracic Surgery

Surgery for acquired cardiovascular disease

Twenty-year experience with the St Jude Medical mechanical valve prosthesis

^a Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, USA

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

Received for publication April 23, 2003; revisions received June 27, 2003; accepted for publication July 7, 2003.

^* Address for reprints: John S. Ikonomidis, MD, PhD, Assistant Professor, Cardiothoracic Surgery, Medical University of South Carolina, Suite 409 CSB, 96 Jonathan Lucas Street, Charleston, SC 29464, USA
ikonomij{at}musc.edu

BACKGROUND: We have prospectively followed all adult St Jude Medical mechanical valve recipients at the Medical University of South Carolina since the initial implant in January 1979 and now present our 20-year experience.

METHODS: We prospectively followed 837 valve recipients (aortic valve replacement; n = 478; mitral valve replacement; n = 359) from January 1979 to December 2000 at 12-month intervals.

RESULTS: Ages ranged from 19 to 84 years. Follow-up averaged (mean ± standard deviation) 7 ± 5 years (98% complete). Patients were in New York Heart Association class III or IV in 77% (aortic valve replacement) and 89% (mitral valve replacement) preoperatively. A 19-mm valve was implanted in 15.5% of aortic valve replacement patients. Coronary bypass was required in 31% of aortic valve replacements and 20% of mitral valve replacements. Operative mortality was 17/478 (3.6%) in aortic valve replacement and 19/359 (5.3%) in mitral valve replacement, and multivariable predictors were 19-mm valve size, 3 or more coronary bypass grafts, and New York Heart Association class IV for aortic valve replacement and New York Heart Association class IV and age for mitral valve replacement. Actuarial survivorship at 10 and 20 years was 57% ± 3% and 26% ± 5% for aortic valve replacement and 61% ± 3% and 39% ± 4% for mitral valve replacement. Multivariable predictors of late death were African-American ethnicity, New York Heart Association class III or IV, coronary bypass, and age for aortic valve replacement and New York Heart Association class III or IV, coronary bypass, and age for mitral valve replacement. For aortic valve replacement, effective orifice area was univariately (P = .002) but not multivariately (P = .378) predictive of late death. Structural valve deterioration was not observed. For aortic valve replacement, actuarial freedom (at 10 and 20 years) from reoperation was 93% ± 1% and 90% ± 2%; thromboembolism, 82% ± 3% and 68% ± 8%; bleeding events, 77% ± 3% and 66% ± 6%; prosthetic valve endocarditis, 94% ± 1% and 94% ± 1%; valve-related mortality, 94% ± 2% and 86% ± 4%; and valve-related mortality or morbidity, 58% ± 3% and 32% ± 8%. For mitral valve replacement, actuarial freedom (at 10 and 20 years) from reoperation was 96% ± 1% and 90% ± 3%; thromboembolism, 77% ± 3% and 59% ± 7%; bleeding events, 86% ± 2% and 65% ± 8%; prosthetic valve endocarditis, 98% ± 1% and 96% ± 2%; valve-related mortality, 89% ± 0.2% and 74% ± 8%; and valve-related mortality or morbidity, 63% ± 3% and 29% ± 7%.

CONCLUSIONS: After 2 decades of observation with close follow-up, the St Jude Medical mechanical valve continues to be a reliable prosthesis.

This article has been cited by other articles:

				F. Edwin, M. M. Tettey, E. Aniteye, L. Sereboe, M. Tamatey, K. Entsua-Mensah, D. Kotei, and K. Frimpong-Boateng Freedom from thromboembolism despite prolonged inadequate anticoagulation BMJ Case Reports, September 15, 2009; 2009(sep15_1): bcr0720092066 - bcr0720092066. [Abstract] [Full Text]

				R. C. Elkins, D. M. Thompson, M. M. Lane, C. C. Elkins, and M. D. Peyton Ross operation: 16-year experience J. Thorac. Cardiovasc. Surg., September 1, 2008; 136(3): 623 - 630. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				Y. S. Tjang, Y. van Hees, R. Korfer, D. E. Grobbee, and G. J.M.G. van der Heijden Predictors of mortality after aortic valve replacement Eur. J. Cardiothorac. Surg., September 1, 2007; 32(3): 469 - 474. [Abstract] [Full Text] [PDF]

				B.-K. Lam, V. Chan, P. Hendry, M. Ruel, R. Masters, P. Bedard, B. Goldstein, F. Rubens, and T. Mesana The impact of patient-prosthesis mismatch on late outcomes after mitral valve replacement J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1464 - 1473. [Abstract] [Full Text] [PDF]

				J. Magne, P. Mathieu, J. G. Dumesnil, D. Tanne, F. Dagenais, D. Doyle, and P. Pibarot Impact of Prosthesis-Patient Mismatch on Survival After Mitral Valve Replacement Circulation, March 20, 2007; 115(11): 1417 - 1425. [Abstract] [Full Text] [PDF]

				A. J. Bryan, C. A. Rogers, K. Bayliss, J. Wild, and G. D. Angelini Prospective randomized comparison of CarboMedics and St. Jude Medical bileaflet mechanical heart valve prostheses: Ten-year follow-up J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 614 - 622. [Abstract] [Full Text] [PDF]

				L. Lau, W.R. E. Jamieson, C. Hughes, E. Germann, and F. Chan What Prosthesis Should Be Used at Valve Re-Replacement After Structural Valve Deterioration of a Bioprosthesis? Ann. Thorac. Surg., December 1, 2006; 82(6): 2123 - 2132. [Abstract] [Full Text] [PDF]

				O. Lund and M. Bland Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 20 - 26. [Abstract] [Full Text] [PDF]

				M. R. Moon, M. K. Pasque, N. A. Munfakh, S. J. Melby, J. S. Lawton, N. Moazami, J. E. Codd, T. D. Crabtree, H. B. Barner, and R. J. Damiano Jr Prosthesis-Patient Mismatch After Aortic Valve Replacement: Impact of Age and Body Size on Late Survival Ann. Thorac. Surg., February 1, 2006; 81(2): 481 - 489. [Abstract] [Full Text] [PDF]

				J. M. Bernal, J. Lorca, D. Prieto-Salceda, I. Pulitani, A. Ponton, I. Garcia, and J. M. Revuelta Performance at 10 years of the CarboMedics 'Top-Hat' valve. Postclamping time is a predictor of mortality Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 144 - 149. [Abstract] [Full Text] [PDF]

				M. Li, J. G. Dumesnil, P. Mathieu, and P. Pibarot Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1034 - 1040. [Abstract] [Full Text] [PDF]

				F. A. Crawford Jr Residual pulmonary artery hypertension after mitral valve replacement: Size matters! J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1041 - 1042. [Full Text] [PDF]

				R. W. Emery, C. C. Krogh, K. V. Arom, A. M. Emery, K. Benyo-Albrecht, L. D. Joyce, and D. M. Nicoloff The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Ann. Thorac. Surg., March 1, 2005; 79(3): 776 - 782. [Abstract] [Full Text] [PDF]